Unitaid and Japan move to align their efforts against tuberculosis

Unitaid and Japan move to align their efforts against tuberculosis

Unitaid Executive Director Lelio Marmora and Parliamentary Vice-Minister for Foreign Affairs of Japan Kenji Yamada met to discuss a new alignment between Japan’s global health priorities and Unitaid’s work in fighting tuberculosis.

The support of Japan will allow Unitaid to carry out two clinical trials whose data will inform World Health Organization (WHO) policy on shorter, better, less-expensive treatments for multidrug-resistant tuberculosis.

Both trials will evaluate regimens that feature delamanid, manufactured by Otsuka Pharmaceutical Co., Ltd. The trials, to be completed in 2022, will involve 1,250 patients in South Africa, Lesotho, Peru, Kazakhstan, Kyrgyzstan, Pakistan and India.

“Japan plays a vital role in accelerating innovation and universal health coverage,” Mr. Marmora said. “The country’s support is fundamental to Unitaid’s mission to expand access to reliable treatments, as part of the global response.”

Through time-limited investments, Unitaid identifies the health innovations with the most potential to alleviate the burden of major diseases and sets the stage for their large-scale introduction by governments and partners such as PEPFAR, the Global Fund and WHO.

Through its support of the Tokyo-based Global Health Innovative Technology Fund (GHIT), Japan is investing in the development of new medicines to combat the rise of drug-resistant strains of TB.

Japan is scheduled to host a meeting of Group of 20 (G20) health ministers on global health priorities in Okayama on 19-20 October. The meeting is one in a series Japan will host in 2019 in its capacity as G20 chair and includes a summit of leaders in Osaka at the end of June.

Original source: Unitaid
Published on 02 April 2019